Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: a retrospective chart review – Kumari S, Manalai P, Leong S, Wooditch A, Malik M, Lawson WB.

July 6, 2017

Background and Objectives Opioid use disorders are common, chronic relapsing disorders. Buprenorphine (BUP) is an FDA approved medication in the treatment of opioid use disorders, but patient adherence to this medication remains a challenge. To identify… (Source: SafetyLit)

Read the full article →

Correlates of nine-month retention following interim buprenorphine-naloxone treatment in opioid dependence: a pilot study – H&#xe5, Kansson A, Widinghoff C, Abrahamsson T, Gedeon C.

July 6, 2017

Interim medication-only treatment has been suggested for the initiation of opioid maintenance treatment (OMT) in opioid-dependent subjects, but this rarely has been studied using buprenorphine instead of methadone. Following a pilot trial assessing interim… (Source: SafetyLit)

Read the full article →

9 Things You Should Know If Your Child Is Using Heroin

July 6, 2017

This article was originally published by The Influence, a news site that covers the full spectrum of human relationships with drugs. Follow The Influence on Facebook or Twitter. References: 1. Huddleston, West, Doug Marlowe and Rachel Casebolt. Painting the Current Picture: A National Report Card on Drug Courts and Other Problem-Solving Court Programs in the […]

Read the full article →

Outdated restrictions 'barrier' to fixing B.C.s overdose crisis, report says

July 6, 2017

A new report blames B.C.’s College of Physicians and Surgeons for not lifting “barriers” to Suboxone, a prescription drug that could dramatically reduce overdose deaths amid a public health emergency. (Source: CBC | Health) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. […]

Read the full article →

Addiction Treatment Industry Worried Lax Ethics Could Spell Its Doom

July 6, 2017

FORT LAUDERDALE, Fla. — The premier organization representing drug treatment providers met in South Florida recently for its annual convention. The theme of this year’s gathering — “The Addiction Industry at a Crossroads” — only hinted at the internal tensions and external pressures reshaping a troubled industry. The opioid epidemic, which just added Prince to its list […]

Read the full article →

Addiction Medicine, Meet Physician Assistants

July 6, 2017

At the recent 2016 annual meeting of the American Academy of PAs (AAPA), the AAPA House of Delegates passed two important resolutions related to the treatment of opioid addiction and the safe prescribing of opiates for pain. The first resolution promotes increased patient access to opiate treatment programs, as well as the full utilization of […]

Read the full article →

Mundipharma and Orexo to launch opioid dependence treatment Zubsolv outside US

July 6, 2017

Mundipharma has signed an agreement with Swedish-based pharmaceutical company Orexo to grant exclusive global (ex-US) rights to Mundipharma’s network of independent associated companies for Zubsolv (buprenorphine and naloxone sublingual tablet), for … (Source: Pharmaceutical Technology)

Read the full article →

Portland addictions specialists welcome Feds’ move to ease treatment restrictions

July 6, 2017

The Obama administration announced it is expanding access to a drug used to treat opioid addiction by raising the cap on how many patients a doctor can treat. Doctors will soon be able to treat 275 patients at a time with buprenorphine, up from 100 currently. The drug, which goes by the brand name Suboxone, […]

Read the full article →

HHS: Medication Assisted Treatment for Opioid Use Disorders

July 6, 2017

This final rule increases access to treatment with buprenorphine and buprenorphine/naloxone, allows eligible practitioners to request approval to treat up to 275 patients, and includes requirements to minimize the risk that medications provided for treatment will be misused or diverted. This rule is effective August 8, 2016. (Source: Federal Register updates via the Rural Assistance […]

Read the full article →

How one physician uses his PDMP to help patients

July 6, 2017

Prescription drug monitoring programs (PDMP) can be an effective clinical tool to assist physicians in making prescribing decisions. Effective PDMPs can help identify red flags in prescription use, and provide information when assessing and making treatment decisions. Learn how one physician in New York uses his PDMP to inform treatment options and discuss safety issues […]

Read the full article →

← Previous Entries

Next Entries →